Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ionis Pharmaceuticals Inc.

www.ionispharma.com

Latest From Ionis Pharmaceuticals Inc.

Bayer/Ionis Advance Next-Generation Antithrombotic After Positive Clinical Results

In a collaboration with Ionis Pharmaceuticals, Bayer is pressing ahead with Phase II clinical studies of an antisense molecule designed to reduce Factor XI production and prevent thrombosis.


Cardiovascular Clinical Trials

Pfizer Reaffirms CV Disease Commitment With Deal For Akcea's ANGPTL3 Drug

Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.

Cardiovascular Deals

R&D Head Ehlers Bows Out As Confidence In Biogen's Pipeline Suffers From Setbacks

EVP Michael Ehlers swaps public company scrutiny for early-stage, venture-funded opportunities at Apple Tree Partners and Limelight Bio, while CMO and longtime Biogen executive Alfred Sandrock reclaims R&D oversight role.

Leadership Business Strategies

US FDA Reassures ALS Patients In Final Development Guidance

ALS advocates succeed in getting the FDA to soften its stance on use of randomized, placebo-controlled trials for drug development; final guidance also encourages patient-reported outcomes.

Neurology Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Isis Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ionis Pharmaceuticals Inc.
  • Senior Management
  • Stanley T Crooke, MD, PhD, Chmn. & CEO
    Elizabeth L Hougen, SVP, Fin. & CFO
    C. Frank Bennett, PhD, SVP, Rsch.
    Damien McDevitt, PhD, CBO
    Richard S Geary, PhD, SVP, Dev.
  • Contact Info
  • Ionis Pharmaceuticals Inc.
    Phone: (760) 931-9200
    2855 Gazelle Ct.
    Carlsbad, CA 92010
    USA
UsernamePublicRestriction

Register